Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020
February 27 2020 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
commercial-stage biopharmaceutical company focused on developing
and commercializing innovative therapies for people with rare
debilitating, chronic neuromuscular and neurological diseases,
today announced its support for Rare Disease Day 2020. Rare Disease
Day, observed on February 29th this year, involves activities
worldwide to raise awareness of rare diseases and their impact on
patients’ lives among the general public and decision-makers in
industry and government.
“We are proud to once again support Rare Disease
Day and the more than 300 million people worldwide afflicted with
rare and ultra-rare diseases,” said Patrick J. McEnany, Chairman
and CEO of Catalyst. “We recognize the importance of investment in
medical research necessary to bring to market new evidence-based
medicines to improve the lives of patients suffering with rare
diseases. We applaud the work of fellow industry members putting
patients’ needs at the forefront as they develop innovative
therapies for the more than 6,000 rare and debilitating
diseases.”
As a public demonstration of support, members of
Catalyst’s team will be joining the National Organization for
Rare Disorders, also known as NORD, in their Show Your Stripes
campaign to raise awareness for rare disease. In addition, Catalyst
is launching its own “Thank Your Physician” campaign. The
average time to diagnosis for a rare disease is 4.8 years. Catalyst
believes it is important to thank physicians who go the extra mile
to diagnose a rare disease earlier in the patient journey. Through
this initiative we will also continue to educate and raise
awareness on the prevalence and challenges of those living with a
rare disease. Among other activities designed to promote awareness
of rare disease and its challenges, Catalyst personnel will also
participate in events and programs including, Patient Coffee
Breaks, Patient Meetups, awareness walks, and educational
activities designed to inform and equip the rare disease
community.
For information about Rare Disease Day activities, visit
https://rarediseases.org/rare-disease-day/.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, including Lambert-Eaton
myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia
gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3.
Catalyst's new drug application for Firdapse® (amifampridine) 10 mg
tablets for the treatment of adults with LEMS was approved in
November 2018 by the U.S. Food & Drug
Administration ("FDA"), and Firdapse is now commercially
available in the United States. Prior to its approval,
Firdapse for LEMS had received breakthrough therapy designation and
orphan drug designation from the FDA.
Firdapse is currently being evaluated in
clinical trials for the treatment of MuSK-MG and SMA Type 3 and has
received Orphan Drug Designation from the FDA for
myasthenia gravis.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2018 and its other
filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on Catalyst's
website, or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024